The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics VANCOUVER, BC, Nov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has commenced clinical research on a testing…


Previous articleThe Serotonin 5-HT2A Receptor: From Mice to Humans
Next articlePsychedelic Bypassing: When Avoidance is Mistaken for Healing